Table: monthly_update_prescription_drug_wac_inc , manufacturer_name like J*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	gross_sales_us_dollars	gross_sales_us_dollars_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000248	Janssen Biotech, Inc.	04/28/2025	57894050301	DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj)Strength: 1800mg / 15 mL Package Size:1 Form:1 single vial	01/28/2025	549.24	10571.87	11/01/2036	Single Source Drug	None	None	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available.
Rx0000248	Janssen Biotech, Inc.	04/28/2025	57894050205	DARZALEX™ (daratumumab)Strength:100 mg 5 mL Package Size:1 Form:1 single vial	01/28/2025	40.30	775.63	09/25/2029	Single Source Drug	None	None	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available.
Rx0000253	Janssen Pharmaceuticals, Inc.	04/28/2025	50458002802	SPRAVATO™ Strength:56 mg Package Size:2 Form:Nasal Spray	01/28/2025	61.79	834.20	02/18/2040	Single Source Drug	None	None	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration data provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2025
Rx0000253	Janssen Pharmaceuticals, Inc.	04/28/2025	50458002803	SPRAVATO™ Strength:84 mg Package Size:3 Form:Nasal Spray	01/28/2025	92.69	1251.31	02/18/2040	Single Source Drug	None	None	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration data provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2025
Rx0000250	Janssen Products, LP	04/28/2025	59676003056	BALVERSA® (erdafitinib) Strength:3 MG Package Size:56 Form:Tablet	01/28/2025	1011.74	21246.54	02/02/2038	Single Source Drug	None	None	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2025.
Rx0000250	Janssen Products, LP	04/28/2025	59676003084	BALVERSA® (erdafitinib) Strength:3 MG Package Size:84 Form:Tablet	01/28/2025	1517.61	31869.81	02/02/2038	Single Source Drug	None	None	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2025.
Rx0000250	Janssen Products, LP	04/28/2025	59676004028	BALVERSA® (erdafitinib) Strength:4 MG Package Size:28 Form:Tablet	01/28/2025	674.49	14164.36	02/02/2038	Single Source Drug	None	None	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2025.
Rx0000250	Janssen Products, LP	04/28/2025	59676004056	BALVERSA® (erdafitinib) Strength:4 MG Package Size:56 Form:Tablet	01/28/2025	1348.99	28328.74	02/02/2038	Single Source Drug	None	None	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2025.
Rx0000250	Janssen Products, LP	04/28/2025	59676005028	BALVERSA® (erdafitinib) Strength:5 MG Package Size:28 Form:Tablet	01/28/2025	843.12	17705.46	02/02/2038	Single Source Drug	None	None	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2025.
Rx0000250	Janssen Products, LP	04/28/2025	59676061001	YONDELIS® (trabectedin) Strength:1 MG Package Size:1 Form:1 Single Vial	01/28/2025	241.36	3689.34	07/07/2028	Single Source Drug	None	None	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2025, and includes a 6 month pediatric extension.
Rx0000008	Jazz Pharmaceuticals, Inc.	04/28/2025	68727080002	Defitelio (Defibrotide Sodium) Injection 80mg/mL Carton of 10 2.5 mL Vials	01/14/2025	400.00	11780.00	06/22/2032	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The current patent expiration date, as defined under the California Code of Regulations § 96070, for Defitelio in the US corresponds to the last to expire of the patents listed in the Approved Products with Therapeutic Equivalence Evaluations (the “Orange Book) as published by the Federal Food and Drug Association as of April 25, 2025.   Unit Sales Volume and Change Improvement: Per CA Health & Safety Code Section 127681(c) Jazz Pharmaceuticals respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000008	Jazz Pharmaceuticals, Inc.	04/28/2025	68727074502	Vyxeos daunorubicin and cytarabine liposome for injection 100mg/20mL, 44 mg/20mL (2 20 mL vial carton)	01/14/2025	625.00	21535.00	10/15/2032	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The current patent expiration date, as defined under the California Code of Regulations § 96070, for Vyxeos in the US corresponds to the last to expire of the patents listed in the Approved Products with Therapeutic Equivalence Evaluations (the “Orange Book) as published by the Federal Food and Drug Association as of April 25, 2025.    Unit Sales Volume and Change Improvement: Per CA Health & Safety Code Section 127681(c) Jazz Pharmaceuticals respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000008	Jazz Pharmaceuticals, Inc.	04/28/2025	68727015001	Xywav (Calcium Oxybate, Magnesium Oxybate, Potassium Oxybate, Sodium Oxybate) 500 MG/ML Oral Solution 180 ml in 1 bottle	01/14/2025	310.00	6590.00	02/22/2041	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The current patent expiration date, as defined under the California Code of Regulations § 96070, for Xywav in the US corresponds to the last to expire of the patents listed in the Approved Products with Therapeutic Equivalence Evaluations (the “Orange Book) as published by the Federal Food and Drug Association as of April 25, 2025.    Unit Sales Volume and Change Improvement: Per CA Health & Safety Code Section 127681(c) Jazz Pharmaceuticals respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.